Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis

Introduction Attention-deficit/hyperactivity disorder (ADHD) is a major public health issue. Pharmacological treatments play an important role in the multimodal treatment of ADHD. Currently, there is a lack of up-to-date and comprehensive evidence on how available ADHD drugs compare and rank in term...

Full description

Bibliographic Details
Main Authors: Cortese, Samuele, Adamo, Nicoletta, Mohr-Jensen, Christina, Hayes, Adrian J., Bhatti, Sahar, Carucci, Sara, Del Giovane, Cinzia, Atkinson, Lauren Z., Banaschewski, Tobias, Simonoff, Emily, Zuddas, Alessandro, Barbui, Corrado, Purgato, Marianna, Steinhausen, Hans-Christoph, Shokraneh, Farhad, Xia, Jun, Cipriani, Andrea, Coghill, David
Format: Article
Published: BMJ Publishing Group 2017
Online Access:https://eprints.nottingham.ac.uk/50111/
_version_ 1848798156923338752
author Cortese, Samuele
Adamo, Nicoletta
Mohr-Jensen, Christina
Hayes, Adrian J.
Bhatti, Sahar
Carucci, Sara
Del Giovane, Cinzia
Atkinson, Lauren Z.
Banaschewski, Tobias
Simonoff, Emily
Zuddas, Alessandro
Barbui, Corrado
Purgato, Marianna
Steinhausen, Hans-Christoph
Shokraneh, Farhad
Xia, Jun
Cipriani, Andrea
Coghill, David
author_facet Cortese, Samuele
Adamo, Nicoletta
Mohr-Jensen, Christina
Hayes, Adrian J.
Bhatti, Sahar
Carucci, Sara
Del Giovane, Cinzia
Atkinson, Lauren Z.
Banaschewski, Tobias
Simonoff, Emily
Zuddas, Alessandro
Barbui, Corrado
Purgato, Marianna
Steinhausen, Hans-Christoph
Shokraneh, Farhad
Xia, Jun
Cipriani, Andrea
Coghill, David
author_sort Cortese, Samuele
building Nottingham Research Data Repository
collection Online Access
description Introduction Attention-deficit/hyperactivity disorder (ADHD) is a major public health issue. Pharmacological treatments play an important role in the multimodal treatment of ADHD. Currently, there is a lack of up-to-date and comprehensive evidence on how available ADHD drugs compare and rank in terms of efficacy and tolerability, in children or adolescents as well as in adults. We will conduct a network meta-analysis (NMA), integrating direct and indirect comparisons from randomised controlled trials (RCTs), to rank pharmacological treatments for ADHD according to their efficacy and tolerability profiles. Methods and analysis We will search a broad range of electronic databases, including PubMed, MEDLINE, EMBASE, PsycINFO, ERIC and Web of Science, with no date or language restrictions. We will also search for unpublished studies using international clinical trial registries and contacting relevant drug companies. We will identify and include available parallel-group, cross-over and cluster randomised trials that compare methylphenidate, dexmethylphenidate, amphetamine derivatives (including lisdexamfetamine), atomoxetine, clonidine, guanfacine, bupropion or modafinil (as oral therapy) either with each other or to placebo, in children, adolescents or adults with ADHD. Primary outcomes will be efficacy (indicated by reduction in severity of ADHD core symptoms measured on a standardised scale) and tolerability (the proportion of patients who left a study early due to side effects). Secondary outcomes will be global functioning, acceptability (proportion of patients who left the study early by any cause) and changes in blood pressure and body weight. NMA will be conducted in STATA within a frequentist framework. The quality of RCTs will be evaluated using the Cochrane risk of bias tool, and the quality of the evidence will be assessed using the GRADE approach. Subgroup and sensitivity analyses will be conducted to assess the robustness of the findings. Ethics and dissemination No ethical issues are foreseen. Results from this study will be published in a peer-reviewed journal and possibly presented at relevant national and international conferences.
first_indexed 2025-11-14T20:15:18Z
format Article
id nottingham-50111
institution University of Nottingham Malaysia Campus
institution_category Local University
last_indexed 2025-11-14T20:15:18Z
publishDate 2017
publisher BMJ Publishing Group
recordtype eprints
repository_type Digital Repository
spelling nottingham-501112020-05-04T18:31:08Z https://eprints.nottingham.ac.uk/50111/ Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis Cortese, Samuele Adamo, Nicoletta Mohr-Jensen, Christina Hayes, Adrian J. Bhatti, Sahar Carucci, Sara Del Giovane, Cinzia Atkinson, Lauren Z. Banaschewski, Tobias Simonoff, Emily Zuddas, Alessandro Barbui, Corrado Purgato, Marianna Steinhausen, Hans-Christoph Shokraneh, Farhad Xia, Jun Cipriani, Andrea Coghill, David Introduction Attention-deficit/hyperactivity disorder (ADHD) is a major public health issue. Pharmacological treatments play an important role in the multimodal treatment of ADHD. Currently, there is a lack of up-to-date and comprehensive evidence on how available ADHD drugs compare and rank in terms of efficacy and tolerability, in children or adolescents as well as in adults. We will conduct a network meta-analysis (NMA), integrating direct and indirect comparisons from randomised controlled trials (RCTs), to rank pharmacological treatments for ADHD according to their efficacy and tolerability profiles. Methods and analysis We will search a broad range of electronic databases, including PubMed, MEDLINE, EMBASE, PsycINFO, ERIC and Web of Science, with no date or language restrictions. We will also search for unpublished studies using international clinical trial registries and contacting relevant drug companies. We will identify and include available parallel-group, cross-over and cluster randomised trials that compare methylphenidate, dexmethylphenidate, amphetamine derivatives (including lisdexamfetamine), atomoxetine, clonidine, guanfacine, bupropion or modafinil (as oral therapy) either with each other or to placebo, in children, adolescents or adults with ADHD. Primary outcomes will be efficacy (indicated by reduction in severity of ADHD core symptoms measured on a standardised scale) and tolerability (the proportion of patients who left a study early due to side effects). Secondary outcomes will be global functioning, acceptability (proportion of patients who left the study early by any cause) and changes in blood pressure and body weight. NMA will be conducted in STATA within a frequentist framework. The quality of RCTs will be evaluated using the Cochrane risk of bias tool, and the quality of the evidence will be assessed using the GRADE approach. Subgroup and sensitivity analyses will be conducted to assess the robustness of the findings. Ethics and dissemination No ethical issues are foreseen. Results from this study will be published in a peer-reviewed journal and possibly presented at relevant national and international conferences. BMJ Publishing Group 2017-01-10 Article PeerReviewed Cortese, Samuele, Adamo, Nicoletta, Mohr-Jensen, Christina, Hayes, Adrian J., Bhatti, Sahar, Carucci, Sara, Del Giovane, Cinzia, Atkinson, Lauren Z., Banaschewski, Tobias, Simonoff, Emily, Zuddas, Alessandro, Barbui, Corrado, Purgato, Marianna, Steinhausen, Hans-Christoph, Shokraneh, Farhad, Xia, Jun, Cipriani, Andrea and Coghill, David (2017) Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis. BMJ Open, 7 (1). e013967/1-e013967/11. ISSN 2044-6055 http://bmjopen.bmj.com/content/7/1/e013967 10.1136/bmjopen-2016-013967 10.1136/bmjopen-2016-013967 10.1136/bmjopen-2016-013967
spellingShingle Cortese, Samuele
Adamo, Nicoletta
Mohr-Jensen, Christina
Hayes, Adrian J.
Bhatti, Sahar
Carucci, Sara
Del Giovane, Cinzia
Atkinson, Lauren Z.
Banaschewski, Tobias
Simonoff, Emily
Zuddas, Alessandro
Barbui, Corrado
Purgato, Marianna
Steinhausen, Hans-Christoph
Shokraneh, Farhad
Xia, Jun
Cipriani, Andrea
Coghill, David
Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis
title Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis
title_full Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis
title_fullStr Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis
title_full_unstemmed Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis
title_short Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis
title_sort comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis
url https://eprints.nottingham.ac.uk/50111/
https://eprints.nottingham.ac.uk/50111/
https://eprints.nottingham.ac.uk/50111/